Evidence map›Paper›PMID 40104634›Full record

ArticleInfectious Disease Modelling2025

Modeling hepatitis B-related deaths in China to achieve the WHO's impact target.

Wenjun Liu, Renjie Liu, Peng Li, Ruyi Xia, Zhuoru Zou, Lei Zhang, Mingwang Shen, Guihua Zhuang

Abstract read
In one paragraph

Article in Infectious Disease Modelling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenjun LiuDepartment of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.
Renjie LiuSchool of Public Health, Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.
Peng LiDepartment of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, PR China.
Ruyi XiaDepartment of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, PR China.
Zhuoru ZouDepartment of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, PR China.
Lei ZhangChina-Australia Joint Research Centre for Infectious Diseases, School of Public Health, Xi'an Jiaotong University Health Science Centre, Xi'an, Shaanxi, PR China.
Mingwang ShenDepartment of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, PR China.
Guihua ZhuangDepartment of Epidemiology and Biostatistics, School of Public Health, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The World Health Organization (WHO) targets a 65% reduction in hepatitis B-related deaths by 2030 compared to 2015 to eliminate viral hepatitis as a major public health threat. It is unknown whether and how China can achieve this target despite significant intervention achievements. We aimed to predict the hepatitis B-related deaths in China and identify key developments needed to achieve the target. Methods: An age- and time-dependent dynamic hepatitis B virus (HBV) transmission compartmental model was developed to predict the trend of hepatitis B-related deaths under base-case and subsequent scenarios from 2015 to 2040. In base-case scenario, we assumed the diagnosis and treatment (D&T) rate would reach 72% in 2030, as proposed by WHO. Subsequent scenarios were set based on the results of base-case and one-way sensitivity analysis. Results: Compared with 2015, hepatitis B-related deaths would be reduced by 23.89% in 2030 and 51.79% in 2040, respectively, and the WHO's impact target of 65% reduction would not be achieved until 2038 at the earliest under base-case scenario. HBV clearance rate and current treatment effectiveness were the most sensitive parameters that significantly influenced the decline of hepatitis B-related deaths from 2015 to 2040. In the subsequent scenario, when D&T rate improving to 90% by 2030, with the current treatment effectiveness and HBV clearance rate being optimized from 2016, the WHO's impact target would be achieved in 2038. Increasing the clearance rate further from 2% to 2.8% during 2016-2030 linearly, the impact target would be achieved on time. Conclusions: It is difficult for China to achieve the WHO's impact target of 65% reduction in hepatitis B-related deaths by 2030 even we assumed the D&T rate would reach 72% in 2030 and beyond. A comprehensive scale-up of available strategies, especially innovative drugs and technologies will ensure that China achieves the target on schedule.

Indexed as

Compartmental modelDiagnosis and treatment rateHepatitis B-Related deathsImpact target

Identifiers

PMID40104634
PMCPMC11915150

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.